Company: JUNS
Filing Date: 2025-11-06
Form Type: DEF 14A
Source: 0001493152-25-020988
Chunk: 79

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-06
Form: DEF 14A
Chunk 79
---
 SEPA, Yorkville will offset the amount due to be paid by Yorkville to the Company
under the SEPA against an equal amount of the Installment Amount, without the Payment Premium, to be paid by the Advance Repayment. If
on the Installment Date any portion of the Installment Amount remains unpaid, the Company must repay such outstanding Installment Amount
as a cash repayment in accordance with this Section.

For so long as any amounts remain outstanding
under either of the Convertible Notes, or unless otherwise agreed by Yorkville, if the Company delivers an Advance Notice under the SEPA,
the Company will be deemed to have elected an Advance Repayment under the Convertible Notes in respect of such Advance Notice up to the
Installment Amount which may or may not be due on an upcoming Installment Date, or subsequent Installment Dates, until all of the outstanding
amounts under both Convertible Notes have been fully repaid. Therefore, until both of the Convertible Notes have been fully repaid, all
proceeds from all advances made under the SEPA will be used solely to repay outstanding amounts under the Convertible Notes, unless Yorkville
agrees otherwise. Thereafter, the net proceeds under the SEPA to the Company will depend on the frequency and prices at which the Company
sells its Common Stock to Yorkville in one or more Advances under the SEPA, and the Company expects that any proceeds received from such
sales to Yorkville in one or more Advances under the SEPA will be used primarily to support its Phase 2 trial of its lead asset, JOTROL,
for the treatment of Parkinson’s Disease and to accelerate direct-to-consumer marketing and sales growth of its recently launched
nutritional product line Nugevia.com, as well as for working capital and other general corporate purposes.

Under the applicable Nasdaq rules, in no event may
the Company issue to Yorkville under the SEPA or upon conversion of the Convertible Notes, collectively, more than 6,638,088 shares
of Common Stock, which number of shares is equal to 19.99% of the shares of Common Stock outstanding immediately prior to the execution
of the SEPA (the “Exchange Cap”), unless the Company obtains the requisite stockholder approval to issue shares of
Common Stock in excess of the Exchange Cap to Yorkville under the SEPA and upon conversion of the Convertible Notes in accordance with
applicable Nasdaq rules. At the upcoming 2025 annual meeting of the Company